What are the most common adverse reactions with Tarceva?
Tarceva has no known contraindications, and its safety profile has been established in more than 2,000 patients in completed clinical trials. In the single-agent NSCLC Phase III trial, the most common side effects-rash and diarrhea-were generally mild to moderate. Each resulted in treatment discontinuation in 1% of Tarceva-treated patients.
In the single-agent phase III SATURN trial evaluating Tarceva as maintenance therapy for NSCLC, the most common adverse reactions, rash and diarrhea, were generally mild to moderate. Rash and diarrhea resulted in treatment discontinuation in 1.2% and 0.5% of Tarceva-treated patients, respectively.
